{"entity":{"id":"nct06235151","kind":"trial","name":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Copper Cu 64 PSMA I&T in prostate cancer, run by Curium US LLC, active and no longer recruiting.","summary":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer is a phase 3 interventional study registered as NCT06235151 by Curium US LLC, with 439 participants enrolled, started 2024-04-01 and due to reach its primary completion in 2026-09. Interventions recorded: Copper Cu 64 PSMA I&T.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06235151","url":"https://clinicaltrials.gov/study/NCT06235151"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["curium"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06235151","phase":"3","setting":"Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging Men With Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy With Pelvic Lymph Node Dissection","sponsor":"Curium US LLC","enrolled":439,"outcomes":[]},"route":"/trials/nct06235151/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/"}]}}